O	0	4	Cost
O	4	5	-
O	5	12	benefit
O	13	21	analysis
O	22	24	of
O	25	26	a
B-intervention	27	33	follow
I-intervention	33	34	-
I-intervention	34	36	up
I-intervention	37	44	program
O	45	47	in
B-eligibility	48	56	patients
I-eligibility	57	61	with
I-eligibility	62	68	breast
I-eligibility	69	75	cancer
O	75	76	:
O	77	78	a
O	79	89	randomized
O	90	101	prospective
O	102	107	study
O	107	108	.

O	109	119	Increasing
O	120	123	the
O	124	130	number
O	131	133	of
O	134	140	breast
O	141	147	cancer
O	148	156	patients
O	157	159	in
O	160	166	follow
O	166	167	-
O	167	169	up
O	170	178	involves
O	179	188	increased
O	189	194	costs
O	195	198	and
O	198	199	,
O	200	204	with
O	205	212	limited
O	213	219	health
O	220	224	care
O	225	234	resources
O	234	235	,
O	236	241	there
O	242	244	is
O	245	246	a
O	247	251	need
O	252	254	to
O	255	263	evaluate
O	264	267	the
O	268	272	cost
O	272	273	-
O	273	280	benefit
O	281	283	to
O	284	287	the
O	288	295	patient
O	296	298	of
O	299	305	follow
O	305	306	-
O	306	308	up
O	309	317	regimens
O	317	318	.

O	319	321	We
O	322	329	present
O	330	331	a
O	332	342	randomized
O	343	354	prospective
O	355	360	study
O	361	363	to
O	364	372	evaluate
O	373	376	the
O	377	381	cost
O	381	382	-
O	382	389	benefit
O	390	392	of
O	393	402	intensive
O	403	409	follow
O	409	410	-
O	410	412	up
O	413	415	in
O	416	419	the
O	420	425	early
O	426	435	detection
O	436	438	of
O	439	447	relapses
O	448	450	in
O	451	459	patients
O	460	464	with
O	465	471	breast
O	472	478	cancer
O	478	479	.

B-total-participants	480	483	One
I-total-participants	484	491	hundred
I-total-participants	492	495	and
I-total-participants	496	502	twenty
I-total-participants	502	503	-
I-total-participants	503	506	one
O	507	515	patients
O	516	520	were
O	521	531	randomized
O	532	534	to
B-control	535	543	standard
I-control	544	552	clinical
I-control	553	559	follow
I-control	559	560	-
I-control	560	562	up
O	563	564	(
O	564	565	n
O	565	566	=
B-control-participants	566	568	63
O	568	569	)
O	570	572	or
O	573	575	to
O	576	578	an
O	579	588	intensive
O	589	595	follow
O	595	596	-
O	596	598	up
O	599	600	(
O	600	601	n
O	601	602	=
B-intervention-participants	602	604	58
O	604	605	)
O	606	610	that
O	611	619	included
O	620	630	diagnostic
O	631	641	laboratory
O	642	647	tests
O	648	651	and
O	652	659	imaging
O	660	668	designed
O	669	671	to
O	672	678	detect
O	679	684	early
O	685	692	relapse
O	693	702	following
O	703	711	curative
O	712	721	treatment
O	721	722	.

O	723	726	All
O	727	735	patients
O	736	739	had
O	740	746	annual
O	747	758	mammography
O	758	759	.

O	760	763	The
O	764	770	number
O	771	773	of
O	774	783	scheduled
O	784	794	outpatient
O	795	807	appointments
O	808	812	kept
O	813	817	were
O	818	821	359
O	822	824	in
O	825	828	the
O	829	837	standard
O	838	846	clinical
O	847	853	follow
O	853	854	-
O	854	856	up
O	857	860	and
O	861	864	355
O	865	867	in
O	868	871	the
O	872	881	intensive
O	882	888	follow
O	888	889	-
O	889	891	up
O	892	897	group
O	897	898	.

O	899	904	After
O	905	906	a
O	907	913	median
O	914	916	of
O	917	918	3
O	919	924	years
O	925	927	of
O	928	934	follow
O	934	935	-
O	935	937	up
O	937	938	,
O	939	944	there
O	945	949	were
O	950	952	28
B-outcome	953	961	relapses
O	961	962	,
B-cv-bin-abs	963	965	11
O	966	968	in
O	969	977	standard
O	978	986	clinical
O	987	993	follow
O	993	994	-
O	994	996	up
O	996	997	,
O	998	1001	and
B-iv-bin-abs	1002	1004	13
O	1005	1007	in
O	1008	1011	the
O	1012	1021	intensive
O	1022	1028	follow
O	1028	1029	-
O	1029	1031	up
O	1032	1037	group
O	1037	1038	.

O	1039	1042	The
B-outcome	1043	1050	overall
I-outcome	1051	1055	cost
I-outcome	1056	1058	of
I-outcome	1059	1065	follow
I-outcome	1065	1066	-
I-outcome	1066	1068	up
O	1069	1072	was
B-cv-cont-mean	1073	1075	24
I-cv-cont-mean	1075	1076	,
I-cv-cont-mean	1076	1079	567
I-cv-cont-mean	1080	1085	euros
O	1086	1088	in
O	1089	1092	the
O	1093	1101	standard
O	1102	1110	clinical
O	1111	1117	follow
O	1117	1118	-
O	1118	1120	up
O	1121	1126	group
O	1127	1130	and
B-iv-cont-mean	1131	1133	74
I-iv-cont-mean	1133	1134	,
I-iv-cont-mean	1134	1137	171
I-iv-cont-mean	1138	1143	euros
O	1144	1146	in
O	1147	1150	the
O	1151	1160	intensive
O	1161	1167	follow
O	1167	1168	-
O	1168	1170	up
O	1171	1176	group
O	1176	1177	.

O	1178	1188	Performing
O	1189	1202	complimentary
O	1203	1217	investigations
O	1218	1220	in
O	1221	1227	breast
O	1228	1234	cancer
O	1235	1241	follow
O	1241	1242	-
O	1242	1244	up
O	1245	1247	is
O	1248	1258	associated
O	1259	1263	with
O	1264	1270	higher
O	1271	1276	costs
O	1277	1284	without
O	1285	1295	difference
O	1296	1298	in
O	1299	1304	early
O	1305	1314	detection
O	1315	1317	of
O	1318	1326	relapses
O	1326	1327	.
